Table 2

Relationship between antigen-specific T cells in peripheral blood (14 days after vaccination) and at vaccination sites (2 days after vaccination)a.

Patient Peptide
ESO1157-167 ESO1157-165 ESO1155-163 Tyrosinase MelanA/MART-1 analogue Influenza
SLLMWITQCFL SLLMWITQC QLSLLMWIT YMDGTMSQV ELAGIGILTV GILGFVFTL
PB VIL PB VIL PB VIL PB VIL PB VIL PB VIL
1145/23 98/534/7 94/90026/5030/90 64/4 44/3
22400403072200
3477110303 61/127 111/2033/12
4112020001326/401928/5
501001102 82/4035/100
6000101000272/372
704000040 58/40 180/10 165/4
8 65/5 230/30NtNtNt0Nt0Nt0 260/20 250/0
9 95/5 188/8Nt0Nt20000 155/50
1008000000160 170/1030/2
Positive 3/10 3/10 0/8 1/9 0/8 0/10 0/9 0/10 3/9 0/10 6/10 3/10

aA positive reaction was scored when more than 40 spots were counted. Shaded areas show positive reactions. The number of spots/background is shown for all positive samples. Abbreviation: PB, peripheral blood; VIL, vaccine infiltrating lymphocytes; Nt, not tested.